Aminoglycoside Administration in Septic Patients

Launched by UNIVERSITY OF THESSALY · Jan 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a type of antibiotic called aminoglycosides in patients who have sepsis or septic shock, particularly those with kidney problems. Sepsis is a serious condition caused by infections that can lead to high mortality rates in intensive care units (ICUs). Aminoglycosides can be effective against certain tough-to-treat bacteria, but they can also harm the kidneys, especially in patients who are already having kidney issues. This study aims to see if using a specific kidney treatment called continuous veno-venous haemodiafiltration can help manage the levels of aminoglycosides in the blood. By doing this, doctors hope to reduce the risk of kidney damage while still effectively treating infections.

To participate in the trial, individuals must be over 18 years old and diagnosed with sepsis or septic shock, have poor kidney function (a measurement called GFR less than 40), and show infection from a specific type of bacteria. Participants will need to have their next of kin sign consent for them to join the study. While involved, participants can expect close monitoring of their kidney function and antibiotic levels to find the best way to use these medications safely. This trial is important because it could lead to better treatment options for patients battling severe infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age \>18 years
• • diagnosis of sepsis or septic shock based on established criteria (Sepsis-3) 29
• • patients with GFR \<40 ml/min
• • microbiemia from a Gram-negative microorganism and for which the attending physician decides to receive an aminoglycoside or sepsis/septic shock for which it is decided to administer it
• • signed consent of the patients' next of kin
• Exclusion Criteria:
• • absence of consent
• • known allergic reaction to aminoglycosides
• • infection from strains resistant to aminoglycosides. As long as the patient has received an aminoglycoside (empirical regimen) and the antibiogram follows it, the treatment can be modified based on the judgment of the attending physician, but the patient's data for the time he received the treatment under consideration are recorded and evaluated
• • unattainable placement of a central venous line for renal replacement therapy